AzTrials
AzTrials

OverweightPhase 3SELECTNCT03574597

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

A Phase 3 study testing Semaglutide in people with Overweight and Obesity, run by Novo Nordisk A/S at 833 sites in 42 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Read more about this study

Who is it for?
Ages 45 years and older
Conditions the study is for
Overweight, Obesity
What is being tested?
Semaglutide
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
17,604 participants
Where
833 sitesin 42 countries
Study dates
24 Oct 2018to 29 Jun 2023
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
  • Male or female, age greater than or equal to 45 years at the time of signing informed consent
  • Body mass index (BMI) greater than or equal to 27 kg/m^2
  • Have established cardiovascular (CV) disease as evidenced by at least one of the following: prior myocardial infarction; prior stroke (ischemic or haemorrhagic stroke); or symptomatic peripheral arterial disease (PAD), as evidenced by intermittent claudication with ankle-brachial index (ABI) less than 0.85 (at rest), or peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease

Who cannot join

  • Cardiovascular-related:
  • Any of the following: myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischaemic attack within the past 60 days prior to the day of screening
  • Planned coronary, carotid or peripheral artery revascularisation known on the day of screening
  • Presently classified as being in New York Heart Association (NYHA) Class IV heart failure
  • Glycaemia-related:
  • HbA1c greater than or equal to 48 mmol/mol (6.5 %) as measured by the central laboratory at screening
Show all 21Show fewer
  • History of type 1 or type 2 diabetes (history of gestational diabetes is allowed)
  • Treatment with glucose-lowering agents within 90 days before screening
  • Treatment with any glucagon-like-peptide-1 receptor agonist (GLP-1 RA) within 90 days before screening
  • General safety:
  • History or presence of chronic pancreatitis
  • Presence of acute pancreatitis within the past 180 days prior to the day of screening
  • Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma
  • End stage renal disease or chronic or intermittent haemodialysis or peritoneal dialysis
  • Presence or history of malignant neoplasms within the past 5 years prior to the day of screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed
  • Severe psychiatric disorder which in the investigator's opinion could compromise compliance with the protocol
  • Known or suspected hypersensitivity to trial products or related products
  • Previous participation in this trial. Participation is defined as randomisation
  • Receipt of any investigational medicinal product within 30 days before screening
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method
  • Any disorder, unwillingness or inability, which in the investigator's opinion, might jeopardise the participant's safety or compliance with the protocol

Trial locations and contacts

833 sites in 42 countries.

833 sites in 42 countries

United States205 sites

  • Albany Medical College - Endo

    Albany, New York, 12203

  • Cambridge Medical Trials

    Alexandria, Louisiana, 71301

  • Inova Cardiology - Mt. Vernon

    Alexandria, Virginia, 23306

  • Ellipsis Group

    Alpharetta, Georgia, 30022

  • Amarillo Med Spec LLP

    Amarillo, Texas, 79106

  • Community Clinical Research_Anderson

    Anderson, Indiana, 46011

  • Internal Medicine Associates of Anderson

    Anderson, South Carolina, 29621

  • Synexus Clin Res US-Anderson

    Anderson, South Carolina, 29621

  • Michigan Medicine

    Ann Arbor, Michigan, 48109

  • Anne Arundel Medical Center

    Annapolis, Maryland, 21401

  • Arlington Family Res. Ctr Inc

    Arlington, Texas, 76012-4637

  • Northwest Heart Clinical Research, LLC

    Arlington Heights, Illinois, 60005

  • University of Colorado Hospital

    Aurora, Colorado, 80045

  • Texas Diab & Endo, P.A.

    Austin, Texas, 78749

  • American Health Network of Indiana, LLC_Avon_0

    Avon, Indiana, 46123

  • University Of Maryland School of Medicine

    Baltimore, Maryland, 21201

  • Ascension Saint Agnes Heart Ca

    Baltimore, Maryland, 21229

  • MedStar Good Samaritan Hosp

    Baltimore, Maryland, 21239

  • UT Health University of Texas

    Bellaire, Texas, 77401

  • Belzoni Clinical Research

    Belzoni, Mississippi, 39038

  • National Heart Institute Cal

    Beverly Hills, California, 90211

  • Central Alabama Research

    Birmingham, Alabama, 35209

  • Univ of Alabama Birmingham

    Birmingham, Alabama, 35294

  • Excel Med Ctr Clinical Trials

    Boca Raton, Florida, 33434

  • Brigham & Women's Hospital

    Boston, Massachusetts, 02115-5804

  • Wade Family Medicine

    Bountiful, Utah, 84010

  • Bradenton Research Center

    Bradenton, Florida, 34205

  • Bridgeport Hospital

    Bridgeport, Connecticut, 06610

  • Holston Medical Group Pc

    Bristol, Tennessee, 37620-7352

  • Dr. Alexander Perkelvald

    Brooklyn, New York, 11229

  • Mercury Street Medical Group, PLLC_Butte

    Butte, Montana, 59701

  • ClinSite LLC.

    Canton, Michigan, 48187

  • UNC Eastowne Clinical Trials Unit

    Chapel Hill, North Carolina, 27514

  • Medical Uni of SC Charleston

    Charleston, South Carolina, 29425

  • OnSite Clinical Solutions, LLC

    Charlotte, North Carolina, 28226

  • Apex Medical Research Inc

    Chicago, Illinois, 60607

  • Mercy Hospital and Medical Center

    Chicago, Illinois, 60616

  • The Carl & Edyth Lindner Center

    Cincinnati, Ohio, 45219

  • Clearwater Cardiovascular Consultants

    Clearwater, Florida, 33756

  • Cleveland Clinic_Cleveland

    Cleveland, Ohio, 44195

  • Optumcare Colorado Springs, LLC

    Colorado Springs, Colorado, 80906

  • Optumcare Colorado Springs

    Colorado Springs, Colorado, 80906

  • Johns Hopkins University

    Columbia, Maryland, 21044

  • Corvallis Clinic PC Clinical Research Department

    Corvallis, Oregon, 97330-3737

  • FDRC

    Costa Mesa, California, 92627

  • Valley Clinical Trials

    Covina, California, 91723

  • Nature Coast Clin Rsrch_Crystal River

    Crystal River, Florida, 34429

  • Thyroid, Endocrinology, and Diabetes, PA

    Dallas, Texas, 75208

  • Texas Health Physicians Group_Dallas

    Dallas, Texas, 75231

  • UT Southwestern Med Cntr

    Dallas, Texas, 75390-9302

  • Geisinger Clinic

    Danville, Pennsylvania, 17822-2111

  • Cardiology Consultants of Danville Inc.

    Danville, Virginia, 24541

  • Providence Health Partners Ctr

    Dayton, Ohio, 45439

  • Florida Premier Cardiology

    Delray Beach, Florida, 33445

  • Henry Ford Health System

    Detroit, Michigan, 48202

  • Doylestown Hospital Pharmacy

    Doylestown, Pennsylvania, 18901

  • Duke University_Durham

    Durham, North Carolina, 27705

  • Durham VA Medical Center - Duke University

    Durham, North Carolina, 27705

  • UniMed Center

    East Brunswick, New Jersey, 08816

  • Centennial Medical Group

    Elkridge, Maryland, 21075-6437

  • MediSphere Medical Research Center, LLC

    Evansville, Indiana, 47714

  • Inova Cardiology-Fairfax

    Fairfax, Virginia, 22031

  • Fleming Island Center for Clinical Research

    Fleming Island, Florida, 32003

  • Northeast Research Institute

    Fleming Island, Florida, 32003

  • Aa Mrc Llc

    Flint, Michigan, 48504

  • Integrative Research Assoc Inc

    Fort Lauderdale, Florida, 33312

  • American Health Network of IN LLC_Franklin

    Franklin, Indiana, 46131

  • WakeMed Garner Hlthplx

    Garner, North Carolina, 27529

  • The Stern Cardiovascular Group

    Germantown, Tennessee, 38138

  • Macoupin Research Group

    Gillespie, Illinois, 62033

  • Synexus Clinical Research US, Inc./Tatum

    Glendale, Arizona, 85306

  • Synexus Clinical Research

    Glendale, Arizona, 85308

  • New West Physicians,Inc.

    Golden, Colorado, 80401

  • St. Vincent Hosp-Prevea Health

    Green Bay, Wisconsin, 54303

  • American Health Network of Indiana, LLC_Greenfield

    Greenfield, Indiana, 46140

  • Physician's East Endocrinology

    Greenville, North Carolina, 27834

  • Palmetto Clinical Research

    Greenville, South Carolina, 29615

  • Louisiana Heart Center

    Hammond, Louisiana, 70403

  • Harleysville Medical Associates

    Harleysville, Pennsylvania, 19438

  • Chicago Medical Research LLC

    Hazel Crest, Illinois, 60429

  • Synexus Clinical Research US

    Henderson, Nevada, 89052

  • Clinical Research of Hollywood_Hollywood

    Hollywood, Florida, 33024

  • Northwest Houston Cardiology, P.A.

    Houston, Texas, 77070

  • PlanIt Research, PLLC

    Houston, Texas, 77079

  • University of Iowa Prev Inter Ctr

    Iowa City, Iowa, 52242

  • Est Cst Inst for Rsrch,Jksnvil

    Jacksonville, Florida, 32216

  • Jacksonville Ctr For Clin Res

    Jacksonville, Florida, 32216

  • Clinical Neuroscience Solutions, Inc.

    Jacksonville, Florida, 32256

  • Baptist Heart Specialists_Jacksonville

    Jacksonville, Florida, 32258

  • Baptist Heart Specialists_Jacksonville Beach

    Jacksonville Beach, Florida, 32250

  • NSC Research, Inc

    Johns Creek, Georgia, 30024

  • Richard M Kastelic MD Assoc

    Johnstown, Pennsylvania, 15905

  • The University Of Kansas Medical Center - Cray Dia

    Kansas City, Kansas, 66160

  • Clinical Inv Spec, Inc.Kenosha

    Kenosha, Wisconsin, 53144

  • Holston Medical Group

    Kingsport, Tennessee, 37660

  • Scripps Whittier Diabetes Inst

    La Jolla, California, 92037

  • Long Island Cardiovascular Consultants PC

    Lake Success, New York, 11042

  • First Valley Medical Group

    Lancaster, California, 93534

  • Palm Research Center Inc-Vegas

    Las Vegas, Nevada, 89128

  • Torrance Clin Res Inst, Inc.

    Lomita, California, 90717

  • Long Beach VA healthcare System

    Long Beach, California, 90822

  • DCOL Ctr for Clin Res

    Longview, Texas, 75605

  • Angel City Research, Inc.

    Los Angeles, California, 90010

  • VAGLAHS Clinical Research Center (CRC)

    Los Angeles, California, 90073

  • Robley Rex VA Medical Center

    Louisville, Kentucky, 40206

  • L-MARC Research Center

    Louisville, Kentucky, 40213

  • Norton Clinical Research Group

    Louisville, Kentucky, 40213

  • Duke University - S.E Cardio

    Lumberton, North Carolina, 28358

  • Advanced Med Res Maumee

    Maumee, Ohio, 43537

  • Clinical Neuroscience Solutions

    Memphis, Tennessee, 38119

  • Reyes Clinical Research, Inc

    Miami, Florida, 33175

  • International Research Associates, LLC_Miami

    Miami, Florida, 33183

  • Franciscan Health Michigan City

    Michigan City, Indiana, 46360

  • Virginia Research Center

    Midlothian, Virginia, 23114

  • Healthscan Clinical Trials,LLC.

    Montgomery, Alabama, 36106

  • Optumcare Colorado Springs, LLC_Monument

    Monument, Colorado, 80132

  • Riverside University Health System Medical Center

    Moreno Valley, California, 92555

  • Burke Primary Care

    Morganton, North Carolina, 28655

  • Accellacare US Inc._SC

    Mt. Pleasant, South Carolina, 29464

  • American Health Network of IN LLC

    Muncie, Indiana, 47304

  • Southern NH Diabetes and Endo_Nashua

    Nashua, New Hampshire, 03060

  • InvestiClin Research

    Nashville, Tennessee, 37203

  • MidState Endocrine Associates

    Nashville, Tennessee, 37203

  • Barnum Medical Research, Inc.

    Natchitoches, Louisiana, 71457-5881

  • American Health Network of Indiana, LLC

    New Albany, Indiana, 47150

  • Yale University School Of Medicine

    New Haven, Connecticut, 06510

  • NYU Grossman School of Med

    New York, New York, 10016

  • NYU School of Medicine

    New York, New York, 10016

  • Comprehensive Weight Ctrl Prog

    New York, New York, 10021

  • York Clinical Research LLC

    Norfolk, Virginia, 23504

  • Strelitz Diabetes Of Eastern V.

    Norfolk, Virginia, 23510

  • Valley Clinical Trials, Inc.

    Northridge, California, 91325

  • Lemah Creek Clinical Research

    Oakbrook Terrace, Illinois, 60181

  • Capital Clin Res Ctr,LLC

    Olympia, Washington, 98502

  • VA NEB - Western IA Health Stm

    Omaha, Nebraska, 68105

  • University of NE Med Ctr

    Omaha, Nebraska, 68198

  • AdventHealth Diab Inst

    Orlando, Florida, 32804

  • Midwest Heart & Vasc Spec

    Overland Park, Kansas, 66211

  • Oviedo Medical Research, LLC

    Oviedo, Florida, 32765

  • MD Medical Research

    Oxon Hill, Maryland, 20745

  • Desert Oasis Hlthcr Med Group

    Palm Springs, California, 92262

  • Hospital of the Univ PA

    Philadelphia, Pennsylvania, 19104-4206

  • Tristar Clin Investigations, PC

    Philadelphia, Pennsylvania, 19114

  • Parkside Family Medicine

    Philadelphia, Pennsylvania, 19144

  • Synexus Rsch /Cnt Phnx Med C

    Phoenix, Arizona, 85050

  • Preferred Primary Care Physicians Inc.

    Pittsburgh, Pennsylvania, 15243

  • Research Institute Of Dallas

    Plano, Texas, 75093

  • Western University of Health Sciences

    Pomona, California, 91766

  • Oregon Health & Science Uni

    Portland, Oregon, 97239

  • Quartz Hill Walk-in Medical Group, inc.

    Quartz Hill, California, 93536

  • Dominion Medical Associates

    Richmond, Virginia, 23219

  • Clinical Research Partners, LLC

    Richmond, Virginia, 23226

  • National Clin Res Inc.

    Richmond, Virginia, 23294

  • Endo And Metab Cons

    Rockville, Maryland, 20852

  • Endocrine Research Solutions

    Roswell, Georgia, 30076

  • East Coast Institute for Research LLC

    Saint Augustine, Florida, 32086

  • VA Medical Center_Salem

    Salem, Virginia, 24153-6404

  • Quality Research Inc

    San Antonio, Texas, 78209

  • Sun Research Institute

    San Antonio, Texas, 78215

  • San Antonio Prem Int Med

    San Antonio, Texas, 78220

  • Physician PrimeCare Research Institute, PLLC dba

    San Antonio, Texas, 78228-6205

  • Audie L. Murphy Va Hospital, Stvhcs

    San Antonio, Texas, 78229

  • VIP Trials

    San Antonio, Texas, 78230

  • TriWest Research Associates

    San Diego, California, 92108

  • San Diego Family Care

    San Diego, California, 92111

  • Mills-Peninsula Medical Center

    San Mateo, California, 94401

  • NorCal Endocrinology and Internal Medicine

    San Ramon, California, 94583

  • Intercoastal Medical Group

    Sarasota, Florida, 34239

  • Saratoga Clinical Research

    Saratoga Springs, New York, 12866

  • Evanston Premier Hlthcr Res

    Skokie, Illinois, 60077

  • NorthShore Univ Hlth Sys

    Skokie, Illinois, 60077

  • Louisiana Heart Center_Slidell

    Slidell, Louisiana, 70458

  • U. of Vermont Med Ctr Burlington

    South Burlington, Vermont, 05403-7205

  • Encompass Clinical Research_Spring Valley

    Spring Valley, California, 91978

  • Central Illinois Diabetes and Clinical Research

    Springfield, Illinois, 62711

  • Amicis Centers of Clinical Research

    St Louis, Missouri, 63128

  • St Louis Heart & Vascular, P.C.

    St Louis, Missouri, 63136

  • Family Health Care Center

    Statesboro, Georgia, 30461

  • Simcare Medical Research, LLC

    Sugar Land, Texas, 77478

  • Houston Center for Clinical Research LLC

    Sugar Land, Texas, 77479

  • Herman Clinical Research LLC

    Suwanee, Georgia, 30024

  • Holy Name Medical Center

    Teaneck, New Jersey, 07666

  • Cotton O'Neil Clin Research Ctr

    Topeka, Kansas, 66606

  • Lundquist Inst-Biomed Innovtn

    Torrance, California, 90502

  • Atlanta Heart Specialists, LLC

    Tucker, Georgia, 30084

  • Trinity Clinical Research LLC

    Tullahoma, Tennessee, 37388

  • Christus Heart and Vascular Institute

    Tyler, Texas, 75701

  • Velocity Clinical_Valparaiso

    Valparaiso, Indiana, 46383

  • Bayview Physician Services

    Virginia Beach, Virginia, 23454

  • Sentara Medical Group_Norfolk

    Virginia Beach, Virginia, 23454

  • Synexus Clinical Research US, Inc._Horsham

    Vista, California, 92083

  • Hillcrest Family Health Center

    Waco, Texas, 76708

  • New Venture Medical Research

    Wadsworth, Ohio, 44281

  • Chase Medical Research LLC

    Waterbury, Connecticut, 06708

  • Aspirus Research Institute

    Wausau, Wisconsin, 54401

  • Cardio Partners Clin Res Inst

    Wellington, Florida, 33449

  • Confluence Health Hospital

    Wenatchee, Washington, 98801

  • Southgate Medical Group, LLP

    West Seneca, New York, 14224

  • Kalo Clinical Research

    West Valley City, Utah, 84120

  • Great Lakes Medical Research

    Westfield, New York, 14787

  • Accellacare

    Wilmington, North Carolina, 28401

  • Selma Medical Associates

    Winchester, Virginia, 22601-3834

  • Amherst Family Practice P.C.

    Winchester, Virginia, 22601

  • PMG Research of Winston-Salem

    Winston-Salem, North Carolina, 27103

  • Trinity Health Michigan Heart

    Ypsilanti, Michigan, 48197

Other trials in United States

Japan49 sites

  • Seiwa Clinic

    Adachi-ku, Tokyo, 123-0845

  • Toyooka Chuo Hospital

    Asahikawa, Hokkaido, 078-8237

  • The Univ. of Tokyo Hp., Dept. of Cardiovascular Medicine

    Bunkyo-ku, Tokyo, 113-8655

  • New Tokyo Heart Clinic_Matsudo-shi, Chiba,

    Chiba, 271-0077

  • Fukuokaken Saiseikai Futsukaichi Hospital_Cardiovascular Medicine

    Chikushino-shi, Fukuoka, 818-8516

  • Ehime Prefectural Central Hospital

    Ehime, 790-0024

  • Chiba Tokushukai Hospital

    Funabashi-shi, Chiba, 274-8503

  • Gifu Heart Center

    Gifu-city, Gifu, 500-8384

  • Hirakata Kohsai Hospital

    Hirakata-shi, Osaka, 573-0153

  • Medical Corporation JR Hiroshima Hospital

    Hiroshima-shi, Hiroshima, 732-0057

  • Hiroshi Yamaguchi Clinic

    Kagoshima-shi, Kagoshima, 892-0828

  • H.E.C Science Clinic

    Kanagawa, 235-0045

  • Kasugai Municipal Hospital

    Kasugai-shi, Aichi, 486-8510

  • Sugiura Clinic

    Kawaguchi-shi, Saitama, 332-0012

  • Steel Memorial Yawata Hospital

    Kitakyushu-shi, Fukuoka, 805-8508

  • Chikamori Hospital

    Kochi-shi, Kochi, 780-8522

  • Saiseikai Kumamoto Hospital

    Kumamoto-shi, Kumamoto, 861-4193

  • Uji Tokushukai Medical Center

    Kyoto, 611-0041

  • Koseikai Takeda Hospital

    Kyoto-shi, Kyoto, 600-8558

  • Ijinkai Takeda General Hospital, Cardiovascular Medicine

    Kyoto-shi,Kyoto, 601-1495

  • Ijinkai Takeda General Hospital, Neurosurgery

    Kyoto-shi,Kyoto, 601-1495

  • Medical Corporation Matsuyama-heartcenter Yotsuba Circulatio

    Matsuyama-shi, Ehime, 790-0062

  • Shinden Higashi Clinic_Miyagi

    Miyagi, 983-0039

  • Shiga General Hospital

    Moriyama-shi, Shiga, 524-8524

  • Nagoya Ekisaikai Hospital

    Nagoya-shi, Aichi, 454-8502

  • Naha City Hospital

    Naha-shi, Okinawa, 902-8511

  • Takagi hospital, Internal Medicine

    Okawa-shi, Fukuoka, 831-0016

  • Okayama Medical Center

    Okayama-shi, Okayama, 701-1192

  • Takatsuki Red Cross Hospital

    Osaka, 569-1045

  • Sakurabashi Watanabe Advanced Healthcare Hospital

    Osaka-city, Osaka, 530-0005

  • Saga University Hospital, Department of Cardiology

    Saga-shi, Saga, 849-8501

  • Shinsapporo Seiryou Hospital, Intenal Medicine

    Sapporo-shi, Hokkaido, 004-0004

  • Hanaoka Seishu Memorial Hospital

    Sapporo-shi, Hokkaido, 062-0003

  • Medical corporation Sanseikai Miyanomori Memorial Hospital

    Sapporo-shi, Hokkaido, 064-8570

  • Sendai Kousei Hospital_Sendai-shi, Miyagi

    Sendai-shi, Miyagi, 980-0873

  • National Center for Global Health and Medicine

    Shinjuku-ku, Tokyo, 162-8655

  • Japan Community Health care Organization Ritsurin Hospital

    Takamatsu-shi, Kagawa, 760-0073

  • Kagawa Prefectural Central Hospital, Cardiovascular Medicine

    Takamatsu-shi, Kagawa, 760-8557

  • Kagawa Prefectural Central Hospital

    Takamatsu-shi, Kagawa, 760-8557

  • Kan-etsu chu-oh Hospital

    Takasaki-shi, Gunma, 370-3513

  • Tokorozawa Heart Center

    Tokorozawa-shi, Saitama, 356-1142

  • Saino Clinic

    Tokorozawa-shi,Saitama, 359-1141

  • Tokyo-Eki Center-building Clinic

    Tokyo, 103-0027

  • Fukuwa Clinic

    Tokyo, 104-0031

  • Tokyo Shinagawa Hospital Social Medical Corporation Association Tokyokyojuno-kai

    Tokyo, 140-8522

  • Minamino Cardiovascular Hospital

    Tokyo, 192-0918

  • National Hospital Organization Saitama National Hospital

    Wako-city, Saitama, 351-0102

  • Nagata Hospital

    Yanagawa-shi, Fukuoka, 832-0059

  • Yokosuka General Hospital Uwamachi, Cardiology

    Yokosuka-shi, Kanagawa, 238-856

Other trials in Japan

Russia49 sites

  • Volosevich First City Clinical Hospital

    Arkhangelsk, 163001

  • Reg. State Budget Healthc. Inst. Regional Clinical Hospital

    Barnaul, 656024

  • City Hospital #5

    Barnaul, 656045

  • RBSHI "Altay Regional Cardiology Dispensary"

    Barnaul, 656055

  • Belgorod regional clinical hospital of the St. Ioasaph

    Belgorod, 308007

  • Cardiological dispensary

    Ivanovo, 153012

  • KSFMU, Inrereginal Clinical Diagnostic center

    Kazan', 420010

  • Institute of Complex Problems of Cardio-Vascular Diseases

    Kemerovo, 650002

  • Medical Center CAPITAL-HEALTH

    Moscow, 109369

  • Moscow City Clinical Hospital #15

    Moscow, 111539

  • Friendship University of Russia

    Moscow, 117292

  • Moscow State University n.a. M.V. Lomonosov

    Moscow, 119991

  • National Medical Research Center of Cardiology

    Moscow, 121552

  • City Clinical Hospital №52

    Moscow, 123182

  • Federal Bureau for Medical and Social Expertise

    Moscow, 127486

  • PHI "Central Clinical Hospital RZD- Medicine"

    Moscow, 129128

  • Moscow City Clinical Hospital n.a. A.K. Eramishantseva

    Moscow, 129327

  • LLC RC Medical

    Novosibirsk, 630005

  • Limited Law Company "Healthy Family" Medicine Center"

    Novosibirsk, 630099

  • LLC Reafan

    Novosibirsk, 630099

  • Scientific Research Institute of neuroscience and Medicine

    Novosibirsk, 630117

  • Orenburg Regional Clinical Hospital

    Orenburg, 460018

  • Penza Regional Clinical Hospital named after N.N. Burdenko

    Penza, 440052

  • Rostov State Medical University_Rostov-on-Don

    Rostov-on-Don, 344068

  • City policlinic #28

    Saint Petersburg, 190013

  • Joint Stock Company "Modern Medical Technologies"

    Saint Petersburg, 190121

  • SPb SBHI City Outpatient clinic #37

    Saint Petersburg, 191119

  • SPb SBHI City Outpatient clinic #109

    Saint Petersburg, 192283

  • Limited Liability Company "Energiya Zdoroviya"

    Saint Petersburg, 194156

  • SPb SBHI City Multifield Hospital #2

    Saint Petersburg, 194354

  • SPb SBHI City polyclinic #117

    Saint Petersburg, 194358

  • FSPbSMU n.a. Academic I.P. Pavlov

    Saint Petersburg, 197022

  • Consultative & Diagnostic Center with a Outpatient Hospital

    Saint Petersburg, 197110

  • Saint-Petersburg "City Policlinic # 74"

    Saint Petersburg, 197762

  • Astarta Clinic LLC

    Saint Petersburg, 199226

  • SPb SBHI City Hospital #38 n.a. N.A. Semashko

    Saint-Petersburg, Pushkin, 196601

  • Regional Clinical cardiological dispensary n.a. Polyakov

    Samara, 443070

  • City Hospital #4, Sochi

    Sochi, 354057

  • SAHI of Komi Republic "Consultative Diagnostic Center"

    Syktyvkar, 167981

  • Tomsk National Research Medical Center of the RAS

    Tomsk, 634012

  • Tomsk Regional Clinical Hospital

    Tomsk, 634041

  • Siberian State Medical University_Tomsk

    Tomsk, 634050

  • Regional Clinical Hospital of Tver

    Tver', 170036

  • Tumen State Medical University

    Tyumen, Russia, 625023

  • Tumen State Medical University - RIMBB

    Tyumen, 625023

  • Ulianovsk Regional Clinical Hospital

    Ulyanovsk, 432063

  • Voronezh Regional Clinical Consultive-diagnostic Centre

    Voronezh, 394018

  • Solovyov Clinical Emergency Hospital

    Yaroslavl, 150003

  • Urals State Medical University

    Yekaterinburg, 620026

Other trials in Russia

United Kingdom42 sites

  • Crouch Oak Family Practice

    Addlestone, KT15 2BH

  • Stroke Trials Office

    Airdrie, ML6 0JS

  • Antrim Area Hospital

    Antrim, BT42 2RL

  • Axbridge & Wedmore Medical Practice

    Axbridge, BS26 2BJ

  • Bermuda Practice

    Basingstoke, RG24 9GT

  • Sea Road Surgery

    Bexhill-on-Sea, TN40 1JJ

  • Birmingham Heartlands Hospital

    Birmingham, B9 5SS

  • Layton Medical Centre

    Blackpool, FY3 7EN

  • Bollington Medical Centre

    Bollington, SK10 5JH

  • The Health Centre

    Bradford on Avon, BA15 1DQ

  • Southmead Hospital

    Bristol, BS10 5NB

  • Ely Bridge Surgery

    Cardiff, CF5 4AD

  • St Peters Hospital, Chertsey

    Chertsey, KT16 0PZ

  • Countess Of Chester NHS Foundation Trust

    Chester, CH2 1UL

  • St. Richards Hospital

    Chichester, West Sussex, PO19 6SE

  • WISDEM Centre

    Coventry, CV2 2DX

  • Ninewells Hospital

    Dundee, DD1 9SY

  • Royal Devon University Healthcare NHS Foundation Trust

    Exeter, EX2 5DW

  • Harrogate District Hospital

    Harrogate, North Yorkshire, HG2 7SX

  • Department Of Cardiac Research

    Harrow, HA1 3UJ

  • Wycombe General Hospital

    High Wycombe, HP11 2TT

  • Hull Royal Infirmary

    Hull, HU3 2JZ

  • Cardiology

    Leicester, LE3 9QP

  • Lincoln County Hospital

    Lincoln, LN2 5QY

  • University Hospital Aintree

    Liverpool, L9 7AL

  • Guys Hospital

    London, SE1 9RT

  • Kings College Hospital

    London, SE5 9RS

  • Imperial College London

    London, W12 0HS

  • Diabetes Centre North Manchester General Hospital

    Manchester, M8 5RB

  • Cardio Research

    Middlesbrough, TS4 3BW

  • University Dept of Medicine, Derriford Hospital, Plymouth

    Plymouth, PL6 8DH

  • Clarence Medical Centre

    Rhyl, LL18 1DA

  • Clifton Medical Centre

    Rotherham, South Yorkshire, S65 1DA

  • Ashfields Primary Care Centre

    Sandbach, CW11 1EQ

  • Clinical Research Unit

    Somerset, BA21 4AT

  • Moorgreen Hospital

    Southampton, SO30 3JB

  • Lister Hospital

    Stevenage, SG1 4AB

  • Sunderland Royal Hospital

    Sunderland, SR4 7TP

  • Musgrove Park Hospital

    Taunton, TA1 5DA

  • Cardiology Department

    Torquay, TQ2 7AA

  • Royal Cornwall Hospital (Treliske)

    Truro, TR1 3LJ

  • University Hospital Wishaw

    Wishaw, ML2 0DP

Other trials in United Kingdom

India34 sites

  • Apex Heart Institute

    Ahmedabad, Gujarat, 380054

  • CIMS- Care Institute of Medical Sciences

    Ahmedabad, Gujarat, 380060

  • Sri Jayadeva Institute of Cardiovascular Sciences & Research

    Bangalore, Karnataka, 560069

  • Narayana Hrudayalya Institute of Cardiac Sciences

    Bangalore, 560 099

  • St John's Medical College and Hospital

    Bangalore, 560034

  • St John's Medical College Hospital

    Bengaluru, Karnataka, 560034

  • SP Medical College

    Bikaner, Rajasthan, 334003

  • The Madras Medical Mission

    Chennai, Tamil Nadu, 600037

  • Kamalnayan Bajaj Hospital

    Chhatrapati Sambhajinagar, Maharashtra, 431010

  • G Kuppuswamy Naidu Memorial Hospital

    Coimbatore, Tamil Nadu, 641037

  • Maulana Azad Medical College

    Delhi, New Delhi, 110002

  • Medanta - The Medicity Multi-Speciality Hospital, Gurugram

    Gurgaon, Haryana, 122001

  • Osmania General Hospital

    Hyderabad, Telangana, 500 012

  • Guru Nanak CARE Hospitals

    Hyderabad, Telangana, 500020

  • B M Birla Heart Research Centre

    Kolkata, West Bengal, 700027

  • Gandhi Memorial Hospital- King George's Medical University

    Lucknow, Uttar Pradesh, 226003

  • Dayanand Medical College & Hospital

    Ludhiana, Punjab, 141001

  • Seth GS medical college and KEM Hospital

    Mumbai, Maharashtra, 400012

  • Lokmanya Tilak Municipal Medical College & General Hospital

    Mumbai, Maharashtra, 400022

  • Holy Family Hospital and Medical Research Centre

    Mumbai, Maharashtra, 400050

  • Arneja Heart & Multispeciality Hospital

    Nagpur, Maharashtra, 440010

  • Shri Krishna Hrudayalaya & Critical Care Centre

    Nagpur, Maharashtra, 440012

  • Vijan Hospital & Research Centre

    Nashik, Maharashtra, 422005

  • All India Institute of Medical Sciences

    New Dehli, New Delhi, 110029

  • VMMC & Safdarjung Hospital

    New Dehli, New Delhi, 110029

  • Batra Hospital and Medical Research Center

    New Delhi, National Capital Territory of Delhi, 110062

  • Dr. BL Kapur Memorial Hospital

    New Delhi, 110005

  • Sir Ganga Ram Hospital

    New Delhi, 110060

  • Grant Medical Foundation

    Pune, Maharashtra, 411001

  • Shri B. D. Mehta Mahavir Heart Institute

    Surat, Gujarat, 395001

  • Unicare heart institute and research centre

    Surat, Gujarat, 395001

  • Nirmal Hospital Pvt. Ltd.

    Surat, Gujarat, 395002

  • Christian Medical College Hospital, Vellore

    Vellore, Tamil Nadu, 632004

  • Ramesh Hospitals

    Vijayawada, Andhra Pradesh, 520008

Other trials in India

Germany31 sites

  • Universitaetsklinikum Aachen AöR

    Aachen, 52074

  • Kardiologische Praxis

    Bad Homburg, 61348

  • Klinische Forschung Berlin (kfgn)

    Berlin, 10117

  • Emovis GmbH

    Berlin, 10629

  • Synexus Berlin

    Berlin, 12627

  • Synexus Bochum

    Bochum, 44787

  • Klinische Forschung Dresden

    Dresden, 01069

  • Hausaerztlich-Kardiologisches MVZ Am Felsenkeller GmbH

    Dresden, 01277

  • Zentrum fuer klinische Studien Suedbrandenburg GmbH

    Elsterwerda, 04910

  • InnoDiab Forschung GmbH

    Essen, 45136

  • Synexus Frankfurt

    Frankfurt, 60313

  • MVZ CCB Frankfurt Und Main-Taunus GbR

    Frankfurt, 60389

  • Denger, Friedrichsthal

    Friedrichsthal, 66299

  • Klinische Forschung Hamburg

    Hamburg, 20253

  • Wendisch/Dahl Hamburg

    Hamburg, 22607

  • Klinische Forschung Hannover

    Hanover, 30159

  • Chevts

    Karlsruhe, 76137

  • Appel

    Kassel, 34121

  • Universitätsklinikum Leipzig, Endokrinologie und Nephrologie

    Leipzig, 04103

  • AmBeNet GmbH

    Leipzig, 04107

  • Universitätsklinikum Schleswig-Holstein

    Lübeck, 23562

  • Die Praxis am Ludwigsplatz

    Ludwigshafen, 67059

  • RED-Institut für medizinische Forschung und Fortbildung GmbH

    Oldenburg in Holstein, 23758

  • Dr. Axthelm Christoph, Pirna

    Pirna, 01796

  • Zentrum für klinische Studien Alexander Segner

    Saint Ingbert-Oberwürzbach, 66386

  • Steindorf, Schkeuditz

    Schkeuditz, 04435

  • Klinische Forschung Schwerin

    Schwerin, 19055

  • Jacob, Villingen-Schwenningen

    Villingen-Schwenningen, 78048

  • Zentrum für klinische Studien Allgäu Oberschwaben

    Wangen, 88239

  • Al-Zoebi

    Wermsdorf, 04779

  • Forschungszentrum Ruhr KliFoCenter GmbH, Dr. med. Kahrmann

    Witten, 58455

Other trials in Germany

Canada28 sites

  • ViaCar Recherche Clinique Inc

    Brossard, Quebec, J4Z 2K9

  • Manna Research Inc. (Burlington N)

    Burlington, Ontario, L7M 4Y1

  • University of Calgary

    Calgary, Alberta, T2T 5C7

  • C-endo Diab Endo Clin Calgery

    Calgary, Alberta, T2V 4J2

  • Cambridge Cardiac Care Centre

    Cambridge, Ontario, N1R 6V6

  • Manna Research Quebec

    Lévis, Quebec, G6W 0M5

  • St. Joseph's Health Care

    London, Ontario, N6A 4V2

  • Manna Research Mirabel

    Mirabel, Quebec, J7J 2K8

  • G.A. Research Associates Ltd.

    Moncton, New Brunswick, E1G 1A7

  • Clinique Sante Cardio MC

    Montreal, Quebec, H1T 3Y7

  • IRCM

    Montreal, Quebec, H2W 1R7

  • Applied Med Inf Res

    Montreal, Quebec, H4A 3T2

  • Manna Research Ottawa

    Nepean, Ontario, K2J 4A7

  • North York Diagn & Cardiac Ctr

    North York, Ontario, M6B 3H7

  • Dr. James Cha

    Oshawa, Ontario, L1J 2K1

  • Kawartha Cardiology Clinical Trials

    Peterborough, Ontario, K9J 0B2

  • Centricity Res Pointe-Claire

    Pointe-Claire, Quebec, H9R 4S5

  • Medical Associates of Port Perry

    Port Perry, Ontario, L9L 1L9

  • Clin des Mal Lipid de Quebec

    Québec, Quebec, G1V 4W2

  • Institut universitaire de cardiologie

    Québec, G1V 4G5

  • Ctr Méd. et pro d l'Ost d port

    Saint-Marc-des-Carrieres, Quebec, G0A 4B0

  • HHI Research Inc.

    Scarborough Village, Ontario, M1B 4Z8

  • Centre de recherché du CHUS

    Sherbrooke, Quebec, J1H 5N4

  • Synergy Wellness Clinic

    Sherwood Park, Alberta, T8H 0N2

  • Manna Research Stoney Creek

    Stoney Creek, Ontario, L8J 3W2

  • Centre de santé et de services

    Terrebonne, Quebec, J6V 2H2

  • The Port Arthur Clinic Research Program

    Thunder Bay, Ontario, P7A 4V7

  • Manna Research Inc._Toronto

    Toronto, Ontario, M9W 4L6

Other trials in Canada

Romania26 sites

  • Minimed S.R.L.

    Bacau, 600238

  • CMI Dr Pop Lavinia

    Baia Mare, Maramureş, 430222

  • Centrul Medical de Diagnostic si Tratament Ambulatoriu Neomed

    Brasov, 500283

  • Sc Nicodiab Srl

    Bucharest, 010507

  • "Carol Davila" Military Emergency Hospital

    Bucharest, 010825

  • Sana Monitoring SRL

    Bucharest, 011025

  • Institutul National de Endocrinologie C.I. Parhon

    Bucharest, 011863

  • SC Eco-Diagnosis SRL

    Bucharest, 031818

  • S.C. Medcon S.R.L

    Buzău, 120203

  • SC Ames Research Center SRL

    Clarasi, Calaras, 910103

  • S.C. Centrul Medical Unirea S.R.L.

    Cluj-Napoca, Cluj, 400349

  • S.C. Top Diabet Srl

    Craiova, Dolj, 200515

  • County Hospital Deva

    Deva, Hunedoara County, 330084

  • S.C Milena Sante SRL

    Galati, 800001

  • SC Diamed Obesity SRL

    Galati, 800291

  • SC Consultmed SRL

    Iași, 700547

  • SC Cardiomed SRL

    Iași, 700687

  • SC Grand Med SRL

    Oradea, Bihor County, 410025

  • S.C. Endodigest S.R.L.

    Oradea, Bihor County, 410151

  • Centrul Medical Bella Praxis

    Paşcani, 700502

  • Bella Praxis S.R.L.

    Paşcani, 705200

  • S.C. Dianutrilife Medica S.R.L.

    Ploieşti, 100561

  • County Emergency Hospital Satu Mare

    Satu Mare, 440055

  • SC Gensan SRL, Policlinica ASTRA

    Sibiu, 550371

  • Sc Mediab Srl

    Târgu Mureş, Mureș County, 540142

  • 3rd Clinic for Nutrition-Spitalulul Județean de Urgenta

    Timișoara, Timiș County, 300736

Other trials in Romania

South Africa25 sites

  • Cardiology Clinical Research

    Alberton, Gauteng, 1450

  • Cardiology Research_Bloemfontein

    Bloemfontein, Free State, 9301

  • IATROS International

    Bloemfontein, Free State, 9301

  • Josha Research

    Bloemfontein, Free State, 9301

  • Dr S Dawood

    Cape Town, Western Cape, 7405

  • Dr Corbett

    Cape Town, Western Cape, 7500

  • Tread Research (Pty)Ltd

    Cape Town, Western Cape, 7500

  • UCT Lung institute

    Cape Town, Western Cape, 7700

  • Dr Iftikhar Osman Ebrahim

    Centurion, Gauteng, 0157

  • Dr Jugnundan's Rooms

    Durban, KwaZulu-Natal, 4091

  • CRISMO

    Germiston, Gauteng, 1401

  • Wits Bara Clinical Trial Site

    Johannesburg, Gauteng, 2013

  • Tickerdoc Research (Pty) LTD

    Johannesburg, Gauteng, 2157

  • WITS Clinical Research

    Johannesburg, Gauteng, 2193

  • Cape Town Medical Research Centre

    Kuilsriver, Western Cape, 7580

  • Dr Moosa's Rooms

    Lenasia, Gauteng, 1827

  • Lenasia Clinical Trial Centre

    Lenasia, Gauteng, 1827

  • Paarl Research Centre

    Paarl, Western Cape, 7646

  • Phoenix Pharma

    Port Elizabeth, Eastern Cape, 6001

  • Jongaie Research

    Pretoria, Gauteng, 0183

  • Synexus Watermeyer Clinical Research Centre

    Pretoria, Gauteng, 0184

  • Clinical Trial Systems (CTC)

    Pretoria, Gauteng, 0186

  • Roodepoort Medicross Clinical Research Centre

    Roodepoort, Gauteng, 1724

  • Synexus Helderberg Clinical Research Centre

    Somerset West, Western Cape, 7130

  • Clinical Projects Research

    Worcester, Western Cape, 6850

Other trials in South Africa

Italy24 sites

  • AO Papa Giovanni XXIII USS Dietologia Clinica

    Bergamo, 24127

  • A. O. Universitaria S.ORSOLA-MALPIGHI - U. O. Endocrinologia

    Bologna, 40138

  • ARNAS Ospedale Garibaldi

    Catania, 95122

  • Università degli studi G. D'Annunzio Chieti Pescara - CAST

    Chieti Scalo, 66100

  • Ospedale di San Fermo della Battaglia

    Como, 22042

  • Azienda Osp-Univ Ferrara-Dip Scienze Mediche-Endocrinologia

    Cona - Ferrara, 44124

  • AOU Careggi Dipartimento Medico Geriatrico SOD Diabetologia

    Florence, 50134

  • U.O.D. Dietetica e Nutrizione Clinica

    Genova, 16132

  • Ospedale Santa Maria Goretti - UOD Diabetologia

    Latina, LT, 04100

  • Azienda Ospedaliera Universitaria Federico II di Napoli

    Naples, 80131

  • Azienda Ospedaliera di Padova Clin.Med.3

    Padova, 35128

  • Unità Funzionale di nutrizione clinica cod 58.01.3

    Palermo, 90127

  • IRCCS Fondazione "S. Maugeri" U.O. Medicina Interna ed Endo

    Pavia, 27100

  • Azienda Ospedaliero Universitaria Pisana Ospedale Cisanello

    Pisa, 56124

  • Pol. Uni. Campus Biomedico UOC Endocrinologia e Diabetologia

    Roma, RM, 00128

  • UOC di Medicina Interna - Centro Medico dell'Obesità

    Roma, 00133

  • Policlinico Universitario AGemelli DH Patologie dell'Obesità

    Rome, 00168

  • Ist.Clinico Humanitas Endocrinologia e Malattie del ricambio

    Rozzano (MI), 20089

  • Centro di Alta Spec. Diet., Educ. Alim. e Prev. Cardio Metab

    San Donato Milanese (MI), MI, 20097

  • Centro di Alta Spec. Diet., Educ. Alim. e Prev. Cardio Metab

    San Donato Milanese (MI), 20097

  • Osp. Santissima Annunziata ASL CN1 Endocrinol. Diabetol.

    Savigliano (CN), 12038

  • IRCCS Multimedica

    Sesto San Giovanni (MI), 20099

  • A.O.U. Senese Policlinico "Le Scotte" , U.O.C. Diabetologia

    Siena, 53100

  • A.O.U. Città della Salute e della Scienza di Torino

    Torino, 10126

Other trials in Italy

Poland22 sites

  • Gabinet Leczenia Otylosci i Chorob Dietozaleznych

    Bialystok, Podlaskie Voivodeship, 15-281

  • Kresmed Sp. z o. o.

    Bialystok, Podlaskie Voivodeship, 15-481

  • Poradnia Kardiologiczna Jaroslaw Jurowiecki

    Gdansk, 80-286

  • Centrum Badan Klinicznych PI-House

    Gdansk, 80-546

  • Centrum Medyczne Pratia Gdynia

    Gdynia, Pomeranian Voivodeship, 81-338

  • PRATIA Centrum Medyczne

    Gdynia, Pomeranian Voivodeship, 81-338

  • Grazyna Pulka Specjalistyczny Osrodek "All-Med"

    Krakow, 30-033

  • UniCardia & UniMedica & UniEstetica

    Krakow, 31-271

  • Centrum Terapii Wspolczesnej

    Lodz, 90-338

  • Klimed Lomza

    Łomża, 18-404

  • ETG Lowicz

    Lowicz, 99-400

  • NZOZ "CenterMed Lublin" Sp. z o.o.

    Lublin, Lublin Voivodeship, 20-044

  • Centrum Zdrowia Metabolicznego

    Poznan, Wielkopolskie Voivodeship, 60-589

  • Centrum Medyczne HCP Sp. z o.o.

    Poznan, 61-485

  • Velocity Nova Sp. z o.o.

    Puławy, 24-100

  • ETG Siedlce

    Siedlce, Masovian Voivodeship, 08-110

  • Clinmedica Research sp. z o.o.

    Skierniewice, Łódź Voivodeship, 96-100

  • Gabinety Lekarskie LabMed

    Szczecin, 71-531

  • ETG Warszawa

    Warsaw, Masovian Voivodeship, 02-677

  • Przychodnia Lekarzy Specjalistow Serce

    Warsaw, 00-416

  • Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji

    Warsaw, 02-507

  • Velocity Zamość

    Zamość, 22-400

Other trials in Poland

Turkey (Türkiye)21 sites

  • Baskent Universitesi Adana

    Adana, 01250

  • Cukurova University School of Medicine Balcali Hospital

    Adana, 01330

  • Gulhane Egitim Arastirma Hastanesi

    Ankara, 06010

  • Hacettepe Universitesi Tip Fakultesi Hastanesi

    Ankara, 06100

  • Akdeniz University Tip Fakultesi Hastanesi

    Antalya, 07058

  • Adnan Menderes Universitesi Uygulama ve Arastirma Hastanesi

    Aydin, 09010

  • Eskisehir Osmangazi University-Cardio

    Eskişehir, 26040

  • Gaziantep Universitesi Tip Fakultesi Hastanesi

    Gaziantep, 27070

  • Koc University Hospital

    Istanbul, 34010

  • Seyrantepe Hamidiye Etfal Egitim ve Arastirma Hastanesi

    Istanbul, 34371

  • Istanbul Universitesi Istanbul Tip Fakultesi - Endokrinoloji

    Istanbul, 34390

  • TC SB Ist.İl Sag.Müd.Prof.Dr.Cemil Tascioglu Sehir Hastanesi

    Istanbul, 34400

  • Fatih Sultan Mehmet Hastanesi

    Istanbul, 34752

  • Umraniye Egitim ve Arastirma Hastanesi

    Istanbul, 34760

  • T.C. Saglik Bakanligi Pendik Egitim ve Arastirma Hastanesi

    Istanbul, 34899

  • Ege University School of Medicine, Cardiology Department

    Izmir, 35100

  • Izmir Tepecik Training and Research Hospital

    Izmir, 35180

  • Dokuz Eylul University School of Medicine, Cardiology

    Izmir, 35340

  • Erciyes University Cardiology

    Kayseri, 38039

  • Mersin University Cardiology

    Mersin, 33343

  • Cumhuriyet University School of Medicine-Cardiology

    Sivas, 58140

Other trials in Turkey (Türkiye)

France17 sites

  • CHRU Besançon

    Besançon, 25030

  • Hôpital Jean Verdier

    Bondy, 93143

  • Centre Hospitalier Sud Francilien

    Corbeil-Essonnes, 91106

  • Centre Hospitalier Universitaire de Dijon-Hopital Le Bocage

    Dijon, 21079

  • Chu Du Bocage

    Dijon, 21079

  • Centre Hospitalier Universitaire Grenoble Alpes-Site Nord Michallon-1

    La Tronche, 38700

  • Les Hopitaux de Chartres-Hopital Louis Pasteur

    Le Coudray, 28630

  • Centre Hospitalier de Narbonne

    Narbonne, 11100

  • CHU de Nice

    Nice, 06000

  • Aphp-Hopital La Pitie Salpetriere-2

    Paris, 75013

  • Ap-Hp-Hopital Europeen Georges Pompidou

    Paris, 75015

  • Hôpital Européen Georges Pompidou

    Paris, 75015

  • Ap-Hp-Hopital Bichat-Claude Bernard-2

    Paris, 75877

  • Centre Hospitalier Universitaire de Bordeaux-Hopital Haut Leveque-2

    Pessac, 33600

  • Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec-1

    Saint-Herblain, 44800

  • Les Hopitaux Universitaires de Strasbourg-Hopital Civil-2

    Strasbourg, 67091

  • Centre de Recherche Clinique Portes Du Sud

    Vénissieux, 69200

Other trials in France

Ukraine17 sites

  • CMI City Clinical Hospital #3

    Chernivtsi, 58000

  • CNPI "Kharkiv City Clinical Hospital #27"

    Kharkiv, 61002

  • NI of Therapy na LT Malaya of NAMSU - Chr. Non-Communicable

    Kharkiv, 61039

  • Oleksandrivska Clinical Hospital - cardio rehabilitation dep

    Kyiv, 01023

  • Medical Center of LLC 'Harmoniya Krasy'

    Kyiv, 01135

  • Medical Center 'Ok!Clinic+' of II of Clinical Studies LLC

    Kyiv, 02091

  • Kyiv City Clinical Hospital of Emergency Care - Infarction

    Kyiv, 02660

  • Clinical Hosp on the railway line №2 branch PHC JSC Ukrzaliz

    Kyiv, 03049

  • MD Strazheska Institute of Cardiology of NAMSU - Resuscitati

    Kyiv, 03151

  • Kyiv Regional Hospital

    Kyiv, 04053

  • City Clinical Emergency Hospital - Cardiology department

    Lviv, 79059

  • Odesa Regional Clinical Hospital

    Odesa, 65025

  • Odessa Clinical Railway Hospital - Outpatient department

    Odesa, 65059

  • City Clinical Hospital #1 - Therapy department

    Vinnytsia, 21000

  • Vinnytsia Regional Clinical Hospital - Cardiology department

    Vinnytsia, 21018

  • Central City Hospital #1 - Scientific-Research center

    Zhytomyr, 10002

  • Zhytomir Regional Clinical Hospital - Cardio-Arrhytm. centre

    Zhytomyr, 10002

Other trials in Ukraine

Bulgaria16 sites

  • Medical Centre Diamedical-2013

    Dimitrovgrad, 6400

  • MHAT Lukovit, Department of Internal Diseases

    Lukovit, 5770

  • "MHAT - Pazardzhik" AD, Second Department of Internal Diseas

    Pazardzhik, 4400

  • "UMBAL-Dr. Georgi Stranski" EAD, First Clinic of cardiology

    Pleven, 5800

  • "UMHAT "Sveti Georgi" EAD

    Plovdiv, 4002

  • Medical centre Razgrad OOD

    Razgrad, 7200

  • "MHAT "NCH" EAD, Cardiology clinic, Noninvasive diag. dep.

    Sofia, 1309

  • "MHAT "NCH" EAD, Clinic of Cardiology, Depart. of Cardiology

    Sofia, 1309

  • "Acibadem City Clinic MHAT Tokuda" EAD,Cardiology department

    Sofia, 1407

  • "Acibadem City Clinic UMHAT" EOOD, Sofia, Cardiology clinic

    Sofia, 1407

  • "Diagnostic - Consulting Center Aleksandrovska" EOOD

    Sofia, 1431

  • "UMHAT "Aleksandrovska" EAD, Cardiology clinic

    Sofia, 1431

  • "UMHAT "Tsaritsa Yoanna-ISUL"" EAD, Clinic of Cardiology

    Sofia, 1527

  • "UMHATEM N.I. Pirogov" EAD

    Sofia, 1606

  • "UMHAT "Sveta Anna" Sofia" AD, Clinic of Cardiology

    Sofia, 1750

  • "Diagnostic - Consulting Center "Ekvita"" EOOD

    Varna, 9002

Other trials in Bulgaria

Brazil15 sites

  • AngioCor Blumenau

    Blumenau, Santa Catarina, 89020-430

  • Hospital do Coração do Brasil

    Brasília, Federal District, 70390-700

  • Instituto de Pesquisa Clínica de Campinas

    Campinas, São Paulo, 13060-080

  • Cline Research Center

    Curitiba, Paraná, 80030-480

  • Núcleo de Pesquisa Clínica S/S

    Curitiba, Paraná, 80730-150

  • Hospital São Vicente de Paulo

    Passo Fundo, Rio Grande do Sul, 99010-080

  • Instituto Brasil de Pesquisa Clinica

    Rio de Janeiro, 20241-180

  • Cárdio Pulmonar da Bahia

    Salvador, Estado de Bahia, 40170130

  • CIP Centro Integrado de Pesquisas do Hospital de Base

    São José do Rio Preto, São Paulo, 15090-000

  • CPQuali Pesquisa Clínica Ltda

    São Paulo, São Paulo, 01228-000

  • CPCLIN - Centro de Pesquisas Clínicas

    São Paulo, São Paulo, 01228-200

  • Instituto Dante Pazzanese de Cardiologia

    São Paulo, São Paulo, 04012-909

  • Departamento de Gastroenterologia - HCFMUSP

    São Paulo, São Paulo, 05403-000

  • Instituto do Coração - HCFMUSP

    São Paulo, São Paulo, 05403-000

  • Eurolatino Medical Research Center

    Uberlândia, Minas Gerais, 38400-500

Other trials in Brazil

Greece14 sites

  • Onassis Cardiac Surgery Center

    Athens, 17674

  • "Laiko" General Hospital of Athens

    Athens, GR-11527

  • Hippokration Hospital

    Athens, GR-11527

  • Alexandra General Hospital, Therapeutic Clinic

    Athens, GR-11528

  • Konstantopouleio G.H. of Athens, "Agia Olga"

    Athens, GR-14233

  • "Hygeia" General Hospital of Athens

    Athens, GR-15123

  • Iatriko Athinon (Athens Medical Canter)

    Athens, GR-15125

  • General Hospital of Chios "Skilitsio"

    Chios, GR82100

  • University Hospital of Athens ATTIKON

    Haidari-Athens, Attica, GR-12462

  • University General Hospital of Ioannina,Internal Medicine

    Ioannina, 45500

  • General Hospital of Lamia

    Lamia, GR35100

  • Univ Gen Hospital Larisa, Cardiology Medicine Clinic

    Larissa, GR-41110

  • AHEPA General University Hospital

    Thessaloniki, GR-54636

  • "Thermi" Private Hosital

    Thessaloniki, GR-57001

Other trials in Greece

Australia13 sites

  • Royal Adelaide Hospital Cardiovascular Clinical Trials

    Adelaide, South Australia, 5000

  • Monash Cardiovascular Research Centre

    Clayton, Victoria, 3168

  • Lyell McEwin Hospital

    Elizabeth Vale, South Australia, 5112

  • The Canberra Hospital_Garran

    Garran, Australian Capital Territory, 2605

  • Geelong Cardiology Research Unit

    Geelong, Victoria, 3220

  • Gosford Hospital

    Gosford, New South Wales, 2250

  • Austin Health, Metabolic Disorders Centre

    Heidelberg Heights, Victoria, 3081

  • HeartCare WA (Joondalup)

    Joondalup, Western Australia, 6027

  • Liverpool Hospital

    Liverpool, New South Wales, 2170

  • Hunter Diabetes Centre

    Merewether, New South Wales, 2291

  • Advara HeartCare

    Milton, Queensland, 4064

  • Core Research Centre

    Milton, Queensland, 4064

  • Cholesterol Care Australia

    Wollongabba, Queensland, 4102

Other trials in Australia

Malaysia13 sites

  • Klinik Kesihatan Masjid Tanah

    Alor Gajah, 78300

  • Hospital Sultanah Bahiyah

    Alor Star, 05460

  • Hospital Universiti Sains Malaysia

    Kota Bharu, Kelantan, 16150

  • Sarawak Heart Centre

    Kota Samarahan, Sarawak, 94300

  • Sarawak Heart Centre

    Kota Samarahan, 94300

  • National Heart Institute

    Kuala Lumpur, 50400

  • University Malaya Medical Centre

    Kuala Lumpur, 59100

  • Hospital Tengku Ampuan Afzan

    Kuantan, Pahang, 25100

  • Hospital Tengku Ampuan Afzan

    Kuantan, 25100

  • Hospital Putrajaya

    Putrajaya, 62250

  • Hospital Queen Elizabeth II

    Sabak Bernam, 88300

  • Hospital Seri Manjung

    Seri Manjung, Perak, 32040

  • University Technology MARA (UiTM) - Puncak Alam

    Sungai Buloh, Selangor, 47000

Other trials in Malaysia

Czechia12 sites

  • Edumed Broumov

    Broumov, 550 01

  • Ordinace pro choroby srdce

    Chomutov, 430 02

  • Fakultni nemocnice Hradec Kralove_Hradec Kralove_0

    Hradec Králové, 500 05

  • Nemocnice Jihlava Kardiologie

    Jihlava, 586 33

  • Kardiologické centrum

    Liberec, 460 63

  • Policska nemocnice

    Polička, 572 01

  • Fakultni poliklinika

    Prague, Czech Republic, 128 08

  • Endocare

    Prague, 140 00

  • ResTrial

    Prague, 181 00

  • Nemocnice Slany Kardiologie

    Slaný, 274 01

  • Svitavska nemocnice Kardiologie

    Svitavy, 568 25

  • Vseobecna kardiologicka ambulance

    Tábor, 39003

Other trials in Czechia

Israel12 sites

  • Outpatient Diabetes Clinic Soroka MC

    Beersheba, 84101

  • Diabetes and obesity center of excellence, Rambam MC

    Haifa, 31096

  • Diabetes Unit Hadassah Ein Karem MC

    Jerusalem, 91120

  • Hadassah Ein Kerem MC - Cardio

    Jerusalem, 91120

  • Clinical Research Unit Meir Medical Center

    Kfar Saba, 44281

  • Institute of Diabetes, Western Galilee MC Nahariya

    Nahariya, 22100

  • Rabin Medical Center - Hasharon Hospital, Dept. D

    Petah Tikva, 49372

  • Kaplan MC

    Rehovot, 76100

  • Cardio Vascular Research Center Sourasky MC

    Tel Aviv, 6423906

  • Institute of Endocrinology, metabolism and hypertension

    Tel Aviv, 64239

  • Endrocrinolgy Clinic - Sheba Medical Center

    Tel HaShomer, 52621

  • Sheba Medica Center - Clinical Research Unit

    Tel HaShomer, 5265601

Other trials in Israel

Spain11 sites

  • Complejo Hospitalario Universitario A Coruña

    A Coruña, 15006

  • Centro Periférico de Especialidades Bola Azul

    Almería, 04009

  • Hospital Gregorio Marañón

    Madrid, 28009

  • Hospital Ramón y Cajal

    Madrid, 28034

  • Hospital Universitario La Paz

    Madrid, 28046

  • Hospital Clínico Virgen de la Victoria

    Málaga, 29010

  • Hospital Son Llatzer

    Palma de Mallorca, 07198

  • Clínica Nuevas Tecnologías en Diabetes y Endocrinología

    Seville, 41003

  • Hospital Virgen de la Macarena

    Seville, 41009

  • Hospital Infanta Luisa

    Seville, 41010

  • Hospital La Fe - Endocrinología y Nutrición

    Valencia, 46026

Other trials in Spain

Argentina10 sites

  • Fundacion Favaloro

    CABA, Buenos Aires, Argentina, C1093AAS

  • Sanatorio Güemes

    CABA, City of Buenos Aires, C1180AAX

  • Centro de Investigación y Prevención Cardiovascular

    CABA, C1061AAS.

  • Centro Médico MEDEOS

    CABA, C1426EGQ

  • Glenny Corp. S.A

    CABA, C1430CKE

  • Clínica Adventista Belgrano

    CABA, C1430EGF

  • Medical Center of Diabetes and Nutrition

    CABA, C1440AAD

  • Instituto Médico DAMIC

    Córdoba, X5003DCE

  • Instituto de Cardiología de Corrientes

    Corrientes, Buenos Aires, W3400AMZ

  • Sanatorio Plaza

    Rosario, S2000

Other trials in Argentina

Netherlands10 sites

  • Gelre Ziekenhuizen Apeldoorn

    Apeldoorn, 7334 DZ

  • Amphia Ziekenhuis

    Breda, 4818 CK

  • Deventer Ziekenhuis

    Deventer, 7416 SE

  • UMC Groningen

    Groningen, 9713 GZ

  • Medisch Centrum Leeuwarden

    Leeuwarden, 8934 AD

  • Alrijne Leiderdorp

    Leiderdorp, 2353 GA

  • Bravis Ziekenhuis

    Roosendaal, 4708 AE

  • Franciscus Gasthuis en Vlietland

    Rotterdam, 3045 PM

  • D & A Research B.V.

    Sneek, 8601 ZR

  • Ziekenhuis Rivierenland Tiel

    Tiel, 4002 WP

Other trials in Netherlands

Mexico9 sites

  • Centro de Investigación Cardiometabólica de Aguascalientes

    Aguascalientes, 20230

  • Centro para el Desarrollo de la Medicina y la Asistencia

    Culiacán, Sinaloa, 80230

  • Lahoja Asociación para la Investigación y Farmacovigilancia

    Durango, 34000

  • Centro de Investigacion Clinica Endocrinologica de Jalisco

    Guadalajara, Jalisco, 44670

  • Instituto Nacional de Cardiología Ignacio Chavez

    Mexico City, México, D.F., 14080

  • Hospital Universitario Dr. José Eleuterio González_Monterrey

    Monterrey, Nuevo León, 64460

  • Unidad Biomedica Avanzada Monterrey

    Monterrey, Nuevo León, 64460

  • Centro de atención e investigación cardiovascular del Potosí

    San Luis Potosí City, San Luis Potosí, 78200

  • CIMAB SA de CV

    Torreón, Coahuila, 27000

Other trials in Mexico

Norway9 sites

  • Ålesund Sjukehus - Hjertemedisinsk poliklinikk

    Ålesund, 6017

  • Haukeland Universitetssykehus

    Bergen, 5021

  • Falck Norge AS

    Hamar, 2317

  • Sykehuset Innlandet Lillehammer

    Lillehammer, 2609

  • Akershus Universitetssykehus

    Nordbyhagen, 1474

  • Rikshospitalet - Kardiologisk forskning

    Oslo, 0372

  • Oslo universitetssykehus HF Ullevål

    Oslo, 0450

  • Oslo universitetssykehus Aker

    Oslo, 0586

  • Senter for sykelig overvekt i Helse Sør-Øst

    Tønsberg, 3117

Other trials in Norway

Thailand9 sites

  • King Chulalongkorn Memorial Hospital_Bangkok

    Bangkok, 10330

  • Phramongkutklao Hospital-cardio

    Bangkok, 10400

  • Phramongkutklao Hospital-neuro

    Bangkok, 10400

  • Ramathibodi Hospital-Cardiovascular metabolic Center

    Bangkok, 10400

  • Siriraj Hospital_Bangkok_1

    Bangkok, 10700

  • Maharaj Nakorn Chiang Mai Hospital

    Chiang Mai, Mueang Chiang Mai District, 50200

  • Maharaj Nakorn Chiang Mai Hospital-cardio

    Chiang Mai, 50200

  • Srinakarind Hospital-Division of Cardiology

    Khon Kaen, 40002

  • Thammasat University Hospital

    Klong Luang, Pathumthani, Changwat Pathum Thani, 12120

Other trials in Thailand

Latvia8 sites

  • Ari Med

    Daugavpils, LV5401

  • Meissana Ltd

    Liepāja, LV-3414

  • Teterovska practice

    Ogre, LV-5001

  • Stradini Cardiology

    Riga, LV-1002

  • Medical Centre Pulss 5

    Riga, LV-1011

  • Adoria

    Riga, LV1011

  • Health Centre-4

    Riga, LV1012

  • Ziemelkurzeme Regional Hospital

    Ventspils, LV3601

Other trials in Latvia

Austria7 sites

  • Universitätsklinik für Innere Medizin

    Graz, 8036

  • Univ.-Klinik für Innere Medizin I

    Innsbruck, 6020

  • LKH Salzburg Universitätsklinikum

    Salzburg, 5020

  • Klinik Landstraße

    Vienna, 1030

  • Ordination Dr. Hanusch

    Vienna, 1060

  • Universitätsklinikum AKH Wien

    Vienna, 1090

  • Klinik Hietzing

    Vienna, 1130

Other trials in Austria

Belgium7 sites

  • Algemeen Stedelijk Ziekenhuis - Aalst - Interventional Cardiology

    Aalst, 9300

  • Imeldaziekenhuis - Bonheiden - Department of Endocrinology

    Bonheiden, 2820

  • CUB Hôpital Erasme_Brussels_1

    Brussels, 1070

  • Ziekenhuis Oost-Limburg AV - Cardiology

    Genk, 3600

  • UZ Gent - Cardiology

    Ghent, 9000

  • UZ Gent_Gent_4

    Ghent, 9000

  • Jessa Ziekenhuis - Hasselt - Cardiology

    Hasselt, 3500

Other trials in Belgium

Colombia7 sites

  • IPS Centro Cientifico Asistencial Jose Luis Accini SAS

    Barranquilla, Atlántico, 080001

  • Fundacion del Caribe para la Investigacion Biomedica-BIOS

    Barranquilla, 080020

  • Clinica de la Costa

    Barranquilla, 80020

  • Unidad de Estudios Clínicos de la Fundación Cardiovascular de Colombia

    Bucaramanga-piedecuesta, Valle Del Menzuli - Santander, Santander Department, 681012

  • Rodrigo Botero S.A.S

    Medellín, Antioquia, 050021

  • Centro de Investigacion Clinica Avanzada y Multidisciplinari

    Medellín, 050021

  • CardiovidCentro Cardiovascular Colombiano ClinicaSantaMaria

    Medellín, 050034

Other trials in Colombia

Croatia7 sites

  • Specijalna bolnica Krapinske Toplice - Kardiologija

    Krapinske Toplice, Krapinsko Zagorska County, 49217

  • Klinicki bolnicki centar Osijek

    Osijek, 31 000

  • KBC Rijeka, Zavod za kardiomiopatije

    Rijeka, 51000

  • Poliklinika Solmed

    Zagreb, City of Zagreb, 10000

  • KBC "Sestre milosrdnice", Kardiologija

    Zagreb, 10000

  • KBC Zagreb, Klinika za bolesti srca i krvnih zila

    Zagreb, 10000

  • Klinicka bolnica Sveti Duh

    Zagreb, 10000

Other trials in Croatia

Finland7 sites

  • StudyCor

    Jyväskylä, 40620

  • Health Step Finland Oy

    Kuopio, 70210

  • Päijät-Häme Central Hospital

    Lahti, 15850

  • OYS Sisätautien tutkimusyksikkö

    Oulu, 90220

  • Seinäjoen keskussairaala

    Seinäjoki, 60220

  • TAYS Sydänsairaala

    Tampere, 33520

  • TYKS Sydänkeskus

    Turku, 20520

Other trials in Finland

Denmark6 sites

  • Aalborg Universitetshospital Kardiologisk Afdeling

    Aalborg, 9000

  • Aarhus Universitetshospital, Skejby Hjertesygdomme

    Aarhus N, 8200

  • Herlev og Gentofte Hospital

    Hellerup, Capital Region, 2900

  • Regionshospitalet Gødstrup, Hjertesygdomme

    Herning, 7400

  • Hvidovre Hospital Hjertemedicinsk

    Hvidovre, 2650

  • Kardiologisk Odense & Svendborg

    Svendborg, 5700

Other trials in Denmark

Hungary6 sites

  • Lausmed Kft.

    Baja, Bács-Kiskun county, 6500

  • Debreceni Egyetem Klinikai Központ Belgyógyászati Klinika

    Debrecen, H-4032

  • Bugát Pál Kórház

    Gyöngyös, 3200

  • Szegedi Tudomanyegyetem St Györgyi Albert Klinikai Központ

    Szeged, Csongrád-Csanád, H-6725

  • Markusovszky Egyetemi Oktatókórház

    Szombathely, H-9700

  • Léda Platán Magánklinika

    Zalaegerszeg, Zala County, 8900

Other trials in Hungary

Ireland6 sites

  • Mater Miscericordiae Hospital

    Dublin, Leinster, D07 XAO9

  • Connolly Hospital

    Dublin, Leinster, DUBLIN 15

  • The Heartbeat Trust

    Dublin, A96 D628

  • St Vincent's Private Hospital

    Dublin, D04 T6F4

  • Tallaght Hospital - Cardiology

    Dublin, D24NR0A

  • Mallow Primary Healthcare Centre

    Mallow, P51Y8EC

Other trials in Ireland

Portugal6 sites

  • Hospital Garcia de Orta

    Almada, 2805-267

  • Centro Hospitalar e Universitário de Coimbra

    Coimbra, 3000-459

  • Hospital da Luz

    Lisbon, 1500-650

  • Centro Hospitalar Lisboa Norte

    Lisbon, 1649-035

  • Unidade Local de Saúde de Matosinhos

    Matosinhos Municipality, 4464-513

  • Centro Hospitalar de São João

    Porto, 4200-319

Other trials in Portugal

Serbia6 sites

  • Clinical centre of Serbia, Clinic for cardiology

    Belgrade, 11000

  • Clinical Centre of Serbia, Emergency Centre, Department of Cardiology

    Belgrade, 11000

  • Emergency Internal Medicine Clinic

    Belgrade, 11000

  • Endocrinology, Diabetes and Metabolism Diseases Clinic

    Belgrade, 11000

  • Special Hospital "Sveti Sava"

    Belgrade, 11000

  • Clin. Centre Vojvodina, Clin. endocr., diab. and met. dis.

    Novi Sad, Vojvodina, 21000

Other trials in Serbia

Sweden6 sites

  • Lundberglab for Diab Research

    Gothenburg, 413 45

  • Centralsjukhuset, Kristianstad

    Kristianstad, 291 85

  • Clemenstorgets Hjärtmottagning

    Lund, 222 21

  • Enheten för Kliniska Studier (EKS), Örebro

    Örebro, 703 62

  • Hjärtenheten

    Östersund, 831 83

  • Karolinska Universitetssjukhuset Solna,FOU Tema Hjärta Kärl

    Stockholm, 171 76

Other trials in Sweden

Algeria5 sites

  • Cardiology department CHU Mustapha Pacha. Algiers

    Algiers, 16000

  • Centre National De la Médecine du Sport

    Algiers, 16000

  • CHU Issad Hassani, Beni Messous, Cardiology department

    Algiers, 16000

  • CHU - Hussein dey Cardiology department Nafissa Hamoud

    Algiers, 16040

  • Cardiology department, Benaouda Benzerdjeb CHU Oran

    Oran, 31000

Other trials in Algeria

Taiwan5 sites

  • HsinChu MacKay Memorial Hospital

    Hsinchu, 300

  • E-DA Hosiptal

    Kaohsiung City, 82445

  • MacKay Memorial Hospital-Tamsui Branch

    New Taipei City, 25160

  • National Taiwan University Hospital

    Taipei, 100

  • Chang Gung Memorial Hospital Linkou

    Taoyuan City, 333

Other trials in Taiwan

Puerto Rico1 site

  • San Miguel Medical

    Trujillo Alto, 00976

Other trials in Puerto Rico

About this study

Official title: SELECT - Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity

The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the participants get is decided by chance. The participant's chance of getting semaglutide or placebo is the same. The participant will get the study medicine in a pen. The participants will need to use the pen to inject the study medicine in a skinfold once a week. The study will last for about 2.5 to 5 years. Participants will have up to 25 clinic visits with the study doctor.

Conditions
Overweight, Obesity
Being tested
Semaglutide, Placebo (semaglutide)
Medical subject headings
Overweight, Obesity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SemaglutideDrug

    Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Subjects will start semaglutide treatment at 0.24 mg; dose will gradually be increased every 4 weeks up to 2.4 mg.

  • Placebo (semaglutide)Drug

    Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Participants will receive placebo at an equivalent dose to semaglutide.

Study groups in NCT03574597
Study groupRoleWhat they receive
SemaglutideExperimentalParticipants will receive semaglutide as an adjunct to standard-of-care. Estimated trial duration for an individual subject is from 31 to 59 months.
Receives: Drug: Semaglutide
Placebo (semaglutide)Placebo comparatorParticipants will receive placebo (semaglutide) as an adjunct to standard-of-care. Estimated trial duration for an individual subject is from 31 to 59 months.
Receives: Drug: Placebo (semaglutide)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke

    Number of participants with first occurrence of composite outcome measure consisted of CV death (undetermined cause of death presumed CV death), non-fatal MI, or non-fatal stroke are presented. The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: From randomisation (week 0) up to 240 weeks

Secondary outcomes (28)

  1. Participants From Time of Randomisation to CV Death

    Number of participants with CV death are presented. The outcome measure was evalulated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: From randomisation (week 0) up to 240 weeks

  2. Participants From Time of Randomisation to First Occurrence of a Composite Heart Failure (HF) Outcome Measure Consisting of: HF Hospitalisation, Urgent HF Visit or CV Death

    Number of participants with first occurrence of a composite HF outcome measure consisted of HF hospitalisation, urgent HF visit or CV death are presented. The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: From randomisation (week 0) up to 240 weeks

  3. Participants From Time of Randomisation to All-cause Death

    Number of participants with all-cause death are presented. The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: From randomisation (week 0) up to 240 weeks

  4. Participants From Time of Randomisation to First Occurrence of an Expanded Composite CV Outcome Measure Consisting of: CV Death, Non-fatal MI, Non-fatal Stroke, Coronary Revascularisation or Unstable Angina Pectoris (UAP) Requiring Hospitalisation

    Number of participants with first occurrence of an expanded composite CV outcome measure consisted of CV death, non-fatal MI, non-fatal stroke, coronary revascularisation or UAP requiring hospitalisation are presented. The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: From randomisation (week 0) up to 240 weeks

  5. Participants From Time of Randomisation to First Occurrence of a Composite Outcome Measure Consisting of: All-cause Death, Non-fatal MI, or Non-fatal Stroke

    Number of participants with first occurrence of a composite outcome measure consisted of all-cause death, non-fatal MI, or non-fatal stroke are presented. The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: From randomisation (week 0) up to 240 weeks

  6. Participants From Time of Randomisation to First Occurrence of Non-fatal MI

    Number of participants with first occurrence of non-fatal MI are presented. The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: From randomisation (week 0) up to 240 weeks

  7. Participants From Time of Randomisation to First Occurrence of Non-fatal Stroke

    Number of participants with first occurrence of non-fatal stroke are presented. The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: From randomisation (week 0) up to 240 weeks

  8. Participants From Time of Randomisation to First Occurrence of Coronary Revascularisation

    Number of participants with first occurrence of coronary revascularisation are presented. The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: From randomisation (week 0) up to 240 weeks

  9. Participants From Time of Randomisation to First Occurrence of UAP Requiring Hospitalisation

    Number of participants with first occurrence of UAP requiring hospitalisation are presented. The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: From randomisation (week 0) up to 240 weeks

  10. Participants From Time of Randomisation to First Occurrence of HF Requiring Hospitalisation or Urgent HF Visit

    Number of participants with first occurrence of HF requiring hospitalisation or urgent HF visit are presented. The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: From randomisation (week 0) up to 240 weeks

  11. Participants From Time of Randomisation to First Occurrence of Glycosylated Haemoglobin (HbA1c) Greater Than Equals to (≥) 48 Millimole Per Mole (mmol/Mol) (6.5 Percentage [%])

    Number of participants with first occurrence of HbA1c ≥ 48 mmol/mol (6.5%) are presented. The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: From randomisation (week 0) up to 240 weeks

  12. Participants From Time of Randomisation to First Occurrence of a 5-component Composite Nephropathy Outcome Measure

    Number of participants with first occurrence of a 5-component composite nephropathy outcome measure consisted of onset of persistent macroalbuminuria (UACR > 300 milligram per gram [mg/g]), persistent 50% reduction in estimated glomerular filtration rate (eGFR) compared with baseline (randomisation), onset of persistent eGFR < 15 ml/min/1.73m^2, initiation of chronic renal replacement therapy (dialysis or transplantation) or renal death. The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: From randomisation (week 0) up to 240 weeks

  13. Participants From Time of Randomisation to HbA1c ≥ 39 mmol/Mol (5.7%) (for Participants With a Screening HbA1c <39 mmol/Mol [5.7%])

    Number of participants with HbA1c ≥ 39 mmol/mol (5.7%) are presented. The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: From randomisation (week 0) up to 240 weeks

  14. Participants With HbA1c < 39 mmol/Mol (5.7%) (for Participants With a Screening HbA1c ≥ 39 mmol/Mol [5.7%])

    Number of participants with HbA1c < 39 mmol/mol (5.7%) are presented. The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: At week 52, week 104

  15. Change in Systolic Blood Pressure (SBP)

    Change in SBP from randomisation (week 0) to week 104 is presented. The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: Week 0, week 104

  16. Change in Diastolic Blood Pressure (DBP)

    Change in DBP from randomisation (week 0) to week 104 is presented. The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: Week 0, week 104

  17. Change in Pulse

    Change in pulse from randomisation (week 0) to week 104 is presented. The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: Week 0, week 104

  18. Change in High Sensitivity C-Reactive Protein (hsCRP) - Ratio to Baseline

    Change in hsCRP (milligram per liter [mg/L]) from randomisation (week 0) to week 104 presented as ratio to baseline (week 0). The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: Week 0, week 104

  19. Change in Total Cholesterol - Ratio to Baseline

    Change in total cholesterol (milligram per deciliter [mg/dL]) from randomisation (week 0) to week 104 is presented as ratio to baseline (week 0). The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: Week 0, week 104

  20. Change in High Density Lipoprotein (HDL) Cholesterol - Ratio to Baseline

    Change in HDL (mg/dL) from randomisation (week 0) to week 104 is presented as ratio to baseline (week 0). The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: Week 0, week 104

  21. Change in Low Density Lipoprotein (LDL) Cholesterol - Ratio to Baseline

    Change in LDL (mg/dL) from randomisation (week 0) to week 104 is presented as ratio to baseline (week 0). The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: Week 0, week 104

  22. Change in Triglycerides - Ratio to Baseline

    Change in triglycerides (mg/dL) from randomisation (week 0) to week 104 is presented as ratio to baseline (week 0). The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: Week 0, week 104

  23. Change in Body Weight

    Percentage change in body weight from randomisation (week 0) to week 104 is presented. The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: Week 0, week 104

  24. Change in Waist Circumference

    Change is waist circumference from randomisation (week 0) to week 104 is presented. The outcome measure was evaluated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: Week 0, week 104

  25. Change From Randomisation (Week 0) in Participant Reported Outcome (PRO): EuroQol Five Dimensions Five Level Questionnaire (EQ-5D-5L) Index Score to Week 104

    EQ-5D-5L is a PRO tool used to estimate impact on participant's health-related quality of life and provides a description of their problems by dimensions (descriptive system). EQ-5D has 5 dimensions: mobility, self-care, usual activities, pain, anxiety/depression, and each dimension has 5 levels: not at all, mild, moderate, severe, extreme. Participant marks most appropriate statement in each dimension, resulting in 1-digit number and digits from 5 dimensions can be combined in 5-digit number describing participant's health state. Index score records an average health status according to dimensions using an algorithm, ranges 0-1 with higher score indicates better health status. Outcome measure was evaluated based on data from in-trial observation period (defined as date of randomisation to one of the dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant [who were lost to follow-up], date of death).

    Measured: Week 0, week 104

  26. Change From Randomisation (Week 0) in PRO: EuroQol Five Dimensions Visual Analogue Scale (EQ-5D-VAS) to Week 104

    EQ-5D-5L is a PRO tool used to estimate impact on participant's health-related quality of life and provides a description of their problems by dimensions (descriptive system). EQ-5D has 5 dimensions: mobility, self-care, usual activities, pain, anxiety/depression, and each dimension has 5 levels: not at all, mild, moderate, severe, extreme. Participant marks most appropriate statement in each dimension, resulting in 1-digit number and digits from 5 dimensions can be combined in 5-digit number describing participant's health state. VAS component records a participant's overall self-rated health on a range of 0-100 with higher score indicates better self-reported health status. Outcome measure was evaluated based on data from in-trial observation period (defined as date of randomisation to one of the dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant [who were lost to follow-up], date of death).

    Measured: Week 0, week 104

  27. Change in HbA1c - Percentage

    Change in HbA1c (percentage) from randomisation (week 0) to week 104 is presented. The outcome measure was evaulated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: Week 0, week 104

  28. Change in HbA1c - mmol/Mol

    Change in HbA1c (mmol/mol) from randomisation (week 0) to week 104 is presented. The outcome measure was evaulated based on data from in-trial observation period. In-trial observation period defined as the period from date of randomisation to one of the following dates, whichever comes first: date of follow-up visit, date when participant withdrew consent, date of last contact with participant for participants who were lost to follow-up (participant did not complete the trial and did not withdraw consent), date of death.

    Measured: Week 0, week 104

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Jul 2018
  2. Study start24 Oct 2018
  3. Primary completion21 Jun 2023
  4. Study completion29 Jun 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
17,604 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03574597
Sponsor's protocol ID
EX9536-4388
Other IDs
2017-003380-35, U1111-1200-5564, 2017
Acronym
SELECT
Status last verified
Aug 2024
First submitted
21 Jun 2018
Last updated
30 Aug 2024
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Publications

  • Ryan DH, Lingvay I, Colhoun HM, Deanfield J, Emerson SS, Kahn SE, Kushner RF, Marso S, Plutzky J, Brown-Frandsen K, Gronning MOL, Hovingh GK, Holst AG, Ravn H, Lincoff AM. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. Am Heart J. 2020 Nov;229:61-69. doi: 10.1016/j.ahj.2020.07.008. Epub 2020 Jul 17.

    PubMed 32916609

  • Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10.

    PubMed 33567185

  • Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornoe CW, Ryan DH; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.

    PubMed 37952131

  • Ostrominski JW, Plutzky J, Scirica BM, Hovingh GK, Jeppesen OK, Lincoff AM, Lingvay I, Hoffmann Morville T, Quiroga M, Sofer Y, Urina-Triana M, Aroda VR; SELECT Trial Investigators. Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial. JAMA Cardiol. 2026 Sep 16:e263566. doi: 10.1001/jamacardio.2026.3566. Online ahead of print.

    PubMed 42747817

  • Sisodia A. Predicting GLP-1 Discontinuation From Pharmacy Claims. Am J Manag Care. 2026 Aug;32(8):426-428. doi: 10.37765/ajmc.2026.89993.

    PubMed 42663544

  • Plutzky J, Bogdanski P, Colhoun HM, Dagdelen S, Deanfield JE, Emerson SS, Hovingh GK, Kahn SE, Ekstrom K, Latkovskis G, Lehrke M, Hardt-Lindberg S, Lingvay I, Nicholls SJ, Kalayci Oral T, Terns PP, Rasmussen S, Ridker PM, Ryan DH, Lincoff AM. Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis. Circulation. 2026 Aug 18. doi: 10.1161/CIRCULATIONAHA.125.074482. Online ahead of print.

    PubMed 42610271

  • Meyhofer SM, Cariou B, Cercato C, Colhoun HM, Deanfield J, Long MT, Jeppesen OK, Lincoff AM, Lingvay I, Plutzky J, Newsome PN, Nicholls SJ, Quiroga M, Santini F, Sanyal AJ, Kahn SE; SELECT Trial Investigators. Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial. Nat Med. 2026 May;32(5):1686-1693. doi: 10.1038/s41591-026-04281-1. Epub 2026 Apr 2.

    PubMed 41928037

  • Nicholls SJ, Ryan DH, Deanfield J, Ferreira D, Lang CC, Lincoff AM, Lingvay I, Lubker C, Terns PP, Rasmussen S, Stensen S, Weeke PE, Kahn SE; SELECT Trial Investigators. Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial. JAMA Cardiol. 2026 Feb 1;11(2):156-164. doi: 10.1001/jamacardio.2025.4824.

    PubMed 41433034

  • Deanfield J, Lincoff AM, Kahn SE, Emerson SS, Lingvay I, Scirica BM, Plutzky J, Kushner RF, Colhoun HM, Hovingh GK, Stensen S, Weeke PE, Jeppesen OK, Bravo R, Wu CC, Komuro I, Santini F, Hjelmesaeth J, Urina-Triana M, Buscemi S, Ryan DH. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet. 2025 Nov 8;406(10516):2257-2268. doi: 10.1016/S0140-6736(25)01375-3. Epub 2025 Oct 22.

    PubMed 41138739

  • Lubker C, Bhavsar J, Duque do Vale R, Emerson SS, Nortoft E, Plutzky J, Roberts G, Tarp JM, Lincoff AM. The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes. Adv Ther. 2025 May;42(5):2513-2525. doi: 10.1007/s12325-025-03176-w. Epub 2025 Mar 29.

    PubMed 40156748

  • McEwan P, Bog M, Faurby M, Foos V, Lingvay I, Lubker C, Miller R, Toliver JC, Yeates F, Lincoff AM. Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes. J Med Econ. 2025 Dec;28(1):268-278. doi: 10.1080/13696998.2025.2459529. Epub 2025 Feb 12.

    PubMed 39882599

  • Badve SV, Bilal A, Lee MMY, Sattar N, Gerstein HC, Ruff CT, McMurray JJV, Rossing P, Bakris G, Mahaffey KW, Mann JFE, Colhoun HM, Tuttle KR, Pratley RE, Perkovic V. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025 Jan;13(1):15-28. doi: 10.1016/S2213-8587(24)00271-7. Epub 2024 Nov 25.

    PubMed 39608381

  • Mendonca L, Moura H, Chaves PC, Neves JS, Ferreira JP. The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes: A Meta-Analysis of Randomized Placebo-Controlled Trials. Clin J Am Soc Nephrol. 2025 Feb 1;20(2):159-168. doi: 10.2215/CJN.0000000584. Epub 2024 Oct 8.

    PubMed 39480988

  • Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ, Emerson SS, Kahn SE, Kitzman DW, Lingvay I, Mahaffey KW, Petrie MC, Plutzky J, Rasmussen S, Ronnback C, Shah SJ, Verma S, Weeke PE, Lincoff AM; SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM Trial Committees and Investigators. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024 Sep 7;404(10456):949-961. doi: 10.1016/S0140-6736(24)01643-X. Epub 2024 Aug 30.

    PubMed 39222642

  • Scirica BM, Lincoff AM, Lingvay I, Bogdanski P, Buscemi S, Colhoun H, Craciun AE, Ezhov M, Hardt-Lindberg S, Kleist Jeppesen O, Matos ALSA, Node K, Schiele F, Toplak H, van Beek A, Weeke PE, Wiviott SD, Deanfield J, Ryan D. The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial. J Am Coll Cardiol. 2024 Oct 22;84(17):1632-1642. doi: 10.1016/j.jacc.2024.08.007. Epub 2024 Aug 30.

    PubMed 39217559

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Semaglutide in people with Overweight and Obesity, run by Novo Nordisk A/S at 833 sites in 42 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 833 sites in United States, Japan, Russia, United Kingdom, India and 37 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 30 Aug 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (time frame: From randomisation (week 0) up to 240 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03574597, which also lists 22 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Aug 2024.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in